First-line Treatment of HER2-positive Recurrent or Metastatic Breast Cancer
| Drug | Drug Name | Drug Description |
|---|
| Drug | Drug Name | Target | Type |
|---|
| Drug | Drug Name | Phase | Status | Count |
|---|---|---|---|---|
| DB18411 | Anbenitamab | 3 | Not Yet Recruiting | 1 |
| DB01248 | Docetaxel | 3 | Not Yet Recruiting | 1 |
| DB06366 | Pertuzumab | 3 | Not Yet Recruiting | 1 |
| DB00072 | Trastuzumab | 3 | Not Yet Recruiting | 1 |